SS Innovations Expands Surgical Robotics Reach with 14,103 Procedures and 238 Systems Installed

SS Innovations International (NASDAQ: SSII), a developer of innovative surgical robotic technologies, has reported continued growth in the use of its SSi Mantra surgical robotic system, with the company’s installed base and procedure count increasing as it expands into new countries and surgical applications. According to an update issued September 10, 238 SSi Mantra systems were installed as of September 8, 2026, up 42% from 168 at the end of 2025. Procedures performed with the system reached 14,103, representing a 79% increase from 7,885 at year-end. The company also said approximately 1,500 physicians have now been trained on SSi Mantra.

The installed base now spans 12 countries, following recent launches in Colombia and Sri Lanka and further international expansion. Pediatric applications continue to expand, including a robotic kidney procedure performed on a 45-day-old infant in India using 5-millimeter instruments. Additionally, SS Innovations reported 188 cumulative robotic telesurgeries as of August 31, alongside long-distance procedures connecting surgeons and patients across countries.

These developments matter because they demonstrate the accelerating adoption of surgical robotics in diverse healthcare settings, potentially improving access to minimally invasive procedures and advancing surgical precision. The growth in procedures and installations indicates increasing trust among medical professionals, which could lead to better patient outcomes and more efficient healthcare delivery. For Texas, a state with a robust healthcare and technology ecosystem, this news highlights the broader trend of innovation in medical devices that can drive economic impact through job creation, research, and improved clinical capabilities.

The company expects FDA review of its 510(k) submission by the end of Q1 2027 and believes EU CE marking for SSi Mantra could be obtained by the end of 2026. These regulatory milestones, if achieved, could further accelerate global market penetration and adoption. The latest news and updates relating to SSII are available in the company’s newsroom at https://ibn.fm/SSII. For full terms of use and disclaimers, see https://IBN.ai/Disclaimer.

Forward-looking statements in this article involve risks and uncertainties that may cause actual results to differ materially. Undue reliance should not be placed on these statements, which are based on information available as of the date hereof. All parties undertake no duty to update this information unless required by law.